Why Is STAAR Surgical Stock Skyrocketing Tuesday? - Staar Surgical (NASDAQ:STAA), Alcon (NYSE:ALC)
SWITZERLAND AND CALIFORNIA, AUG 5 – Alcon will pay a 59% premium to acquire STAAR Surgical for $1.5 billion to expand its implantable lens offerings amid rising global myopia rates.
- On August 5, 2025, STAAR Surgical agreed to be acquired by Alcon for $28 per share in cash, valuing the deal at about $1.5 billion.
- The sale follows STAAR's financial challenges and fluctuating demand in China, with shareholder approval still required and a fairness investigation underway.
- Alcon expects the acquisition to strengthen its surgical vision correction offerings, especially for patients unsuitable for other surgeries like LASIK, amid rising severe myopia globally.
- The $28 per share price represents a roughly 59% premium to STAAR's recent average, and analysts note this deal bolsters Alcon’s market position despite STAAR’s setbacks in China.
- The transaction is expected to close within six to twelve months, become accretive to Alcon's earnings by year two, and expand treatment options across the myopia spectrum.
Insights by Ground AI
Does this summary seem wrong?
15 Articles
15 Articles

+2 Reposted by 2 other sources
Alcon announces purchase of STARR Surgical for $1.5 billion
Alcon, an international eye care company with facilities in Berks County, has announced it plans to acquire STAAR Surgical Co. Under the terms of the agreement announced Tuesday, Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, in a deal valued at approximately $1.5 billion. Alcon said it plans to finance the transaction through the issuance of short- and long-term credit facilities. The transaction is …
·Pennsylvania, United States
Read Full ArticleCoverage Details
Total News Sources15
Leaning Left1Leaning Right0Center6Last UpdatedBias Distribution86% Center
Bias Distribution
- 86% of the sources are Center
86% Center
14%
C 86%
Factuality
To view factuality data please Upgrade to Premium